ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 707

Different Location and Extent Of Impaired Perfusion Of The Choroid Plexus In Primary and Secondary Raynaud’s Phenomenon

Francesca Ingegnoli1, Roberta Gualtierotti2, Luisa Pierro3, Elisabetta Miserocchi4, Giulio Modorati5, Claudia Del turco3, Marco Gagliardi3, Giuseppe Parrinello6, Tommaso Schioppo2 and Pier Luigi Meroni7, 1Dept. of clinical sciences and community health, Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy, 2Dept. of clinical sciences and community health, Division of Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy, 3Department of Ophthalmology, Vita-Salute University, San Raffaele Scientific Institute, Milano, Italy, 4Department of Ophthalmology, Scientific Institute San Raffaele, University Vita-Salute, Milan, Italy, 5San Raffaele Scientific Institute, Ocular immunology and uveitis service, Milano, Italy, 6Department of Ophthalmology,, Vita-Salute University, San Raffaele Scientific Institute, Milano, Italy, 7Division of Rheumatology, Gaetano Pini Institute, Milano, Italy

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Raynaud's phenomenon and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s - Clinical Aspects and Therapeutics I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Raynaud’s phenomenon (RP) is a disorder characterized by systemic vascular dysregulation which has been related with vasospasms and retinal blood flow abnormalities. Nevertheless among the potential complications of RP, eye involvement is often overlooked. The aim of this study was to evaluate the presence of vascular eye involvement measuring the choroidal and macular thickness in a cross-sectional cohort of RP at the first rheumatologic evaluation.

Methods: thirty adult consecutive RP, without visual symptoms, underwent: clinical evaluation and nailfold capillaroscopy. Sera were tested for anti-nuclear antibodies, anti-dsDNA, anti-extractable nuclear antigens. Patients underwent a complete ocular examination including: best corrected visual acuity; slit lamp biomicroscopy; intraocular pressure measurements and fundus examination; choroidal thickness by Zeiss Cirrus Spectral Domain Optical Coherence Tomography with enhanced depth imaging scan system at the fovea and up to 2 mm at intervals of 1 mm from the fovea in the superior, inferior, nasal and temporal choroid; central foveal thickness (CFT) was also measured. 27 healthy, sex and age-matched, subjects were analysed as control group. Statistical analysis was performed by one-way ANOVA and multiple comparisons.

Results: eight primary RP (pRP) (median age 53 yrs), 12 early systemic sclerosis (SSc) (median age 57 yrs), 10 RP secondary to suspected connective tissue disease (CTD) (i.e. capillaroscopy abnormalities or antibody positivity and without any symptoms/signs suggesting a CTD) (median age 54 yrs). Slit lamp biomicrocopy was within normal limits in all patients and fundus examination revealed normal arterial and venous vessels with no capillary abnormalities. The mean best corrected visual acuity was 20/40 and the mean intraocular pressure measurement was 14 mmHg. In pRP, mean choroidal thickness was significantly thinner than healthy controls in the outer nasal (224.8μm vs 289μm; p<0.05) and outer temporal (263.3μm vs 299μm; p<0.05) regions. In patients with RP secondary to suspected CTD the inner and outer nasal were significantly thinner (244.1μm vs 297.4μm; p<0.05 and 199.7μm vs 289μm; p<0.0001 respectively). In SSc all the areas examined were significantly thinner than healthy controls except for the inner temporal region which however was decreased: central (250.5μm vs 313.2μm; p<0.01), inner inferior (239.9μm vs 293.1μm; p<0.05), inner nasal (221μm vs 297.4μm; p<0.001), inner superior (243.9μm vs 293.2μm; p<0.05), outer temporal (219.3μm vs 299μm; p<0.001), outer inferior (229.9μm vs 289.8 μm; p<0.001), outer nasal (187μm vs 289μm; p<0.001), outer superior (240.4μm vs 293.3μm; p<0.05). CFT was also thinner in all the patients than healthy controls although not significant.

Conclusion: A thinner choroidal and macular thickness was observed in all the patients, with progressive decrease from pRP to SSc. These data suggest an early involvement of ocular microcirculation with significant reduction of choroidal perfusion. This process likely starts from the external regions (outer nasal and temporal) in pRP, and becomes more severe and extensive in RP secondary to a suspected CTD and even more severe and in SSc.


Disclosure:

F. Ingegnoli,
None;

R. Gualtierotti,
None;

L. Pierro,
None;

E. Miserocchi,
None;

G. Modorati,
None;

C. Del turco,
None;

M. Gagliardi,
None;

G. Parrinello,
None;

T. Schioppo,
None;

P. L. Meroni,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/different-location-and-extent-of-impaired-perfusion-of-the-choroid-plexus-in-primary-and-secondary-raynauds-phenomenon/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology